Brief: Zevra Therapeutics Announces Positive Final Results From Phase 2 Clinical Trial Of Kp1077 For Idiopathic Hypersomnia
03/06/2024 18:12
June 3 (Reuters) - Zevra Therapeutics Inc ZVRA.O :
* ZEVRA THERAPEUTICS ANNOUNCES POSITIVE FINAL RESULTS FROM PHASE 2 CLINICAL TRIAL OF KP1077
FOR
IDIOPATHIC HYPERSOMNIA AT SLEEP 2024 ANNUAL MEETING
* ZEVRA THERAPEUTICS INC - KP1077 WAS WELL TOLERATED
Source text for Eikon: ID:nGNX4RGvrJ
Further company coverage: ZVRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zevra Therapeutics
See all newsZevra Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Zevra Therapeutics Q2 revenue rises 53% on MIPLYFFA sales
Zevra Therapeutics Inc expected to post earnings of 11 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Tenet, SLB, Digital Realty
U.S. STOCKS ON THE MOVE-Booz Allen Hamilton, Sensient, Amkor